Capricor Therapeutics Inc (OTCMKTS:CAPR) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02, Bloomberg Earnings reports. The business had revenue of $1 million during the quarter, compared to the consensus estimate of $1.10 million.

Capricor Therapeutics (OTCMKTS:CAPR) traded down 4.67% on Friday, hitting $1.02. The stock had a trading volume of 207,336 shares. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.09. The firm’s market cap is $23.05 million. The firm’s 50-day moving average price is $0.94 and its 200-day moving average price is $2.02.

CAPR has been the subject of several recent analyst reports. HC Wainwright set a $2.00 price target on Capricor Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Zacks Investment Research raised Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Monday, April 17th. Rodman & Renshaw reissued a “buy” rating and issued a $2.15 price target on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. Finally, ValuEngine cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $4.91.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/capricor-therapeutics-inc-otcmktscapr-releases-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.

An institutional investor recently raised its position in Capricor Therapeutics stock. LLBH Private Wealth Management LLC raised its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 27.7% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 184,591 shares of the biotechnology company’s stock after buying an additional 40,000 shares during the period. LLBH Private Wealth Management LLC owned about 0.82% of Capricor Therapeutics worth $153,000 at the end of the most recent reporting period.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.